Difference between revisions of "Template:HypericumInfo"

From Psychiatrienet
Jump to: navigation, search
Line 1: Line 1:
 
* Hypericum induces enzymes of the [[wp:Cytochrome P450 reductase|CYP P-450]] type and P-gp type.
 
* Hypericum induces enzymes of the [[wp:Cytochrome P450 reductase|CYP P-450]] type and P-gp type.
* Hypericum might have [[wp:Monoamine oxidase inhibitor|MAO-inhibiting]] and/or [[wp:COMT inhibitor|COMT-inhibiting]] properties.
+
* Hypericum might have [[wp:Monoamine oxidase inhibitor|MAO-inhibiting]] and/or [[wp:COMT inhibitor|COMT-inhibiting]] properties.  
 +
* Many studies reported that hypericin is the main source of pharmacological effects of hypericum. The IC50 of hypericin to inhibit MAO A and MAO B is 100- to 1000-fold higher than accessible Cmax values of hypericin after oral administration of hypericum.<ref name ="Wurglics2006">{{Pubmed|16640452|Wurglics M, Schubert-Zsilavecz M.Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.}}</ref>
 +
* the T1/2 of hypericum is 19 - 37 hour.<ref name="informatorium" />

Revision as of 14:40, 15 August 2011

  • Hypericum induces enzymes of the CYP P-450 type and P-gp type.
  • Hypericum might have MAO-inhibiting and/or COMT-inhibiting properties.
  • Many studies reported that hypericin is the main source of pharmacological effects of hypericum. The IC50 of hypericin to inhibit MAO A and MAO B is 100- to 1000-fold higher than accessible Cmax values of hypericin after oral administration of hypericum.[1]
  • the T1/2 of hypericum is 19 - 37 hour.[2]
  • Wurglics M, Schubert-Zsilavecz M.Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.
  • Cite error: Invalid <ref> tag; no text was provided for refs named informatorium